Hygen Pharmaceuticals Inc.

Hygen Pharmaceuticals Inc., a minority-owned, SBA 8(a)-certified small disadvantaged business based in Redmond, Washington, supplies prescription and specialty pharmaceuticals to the Department of Veterans Affairs as a prime contractor across multiple Veterans Integrated Service Networks, operating exclusively under total small business set-asides and full-and-open competitions that do not use set-asides.

Hygen is a Subchapter S corporation and Subcontinent Asian (Asian-Indian) American–owned entity that operates under NAICS 325412 (Pharmaceutical Preparation Manufacturing) and PSC category "Drugs and Biologicals." The company's federal footprint centers entirely on pharmaceutical distribution to VA Consolidated Mail Outpatient Pharmacies (CMOPs) nationwide, delivering both routine maintenance medications and controlled substances. Representative work includes a $130,949.28 purchase order from Veterans Integrated Service Network 22 (awarded August 27, 2024) for Sumatriptan Injection Syringe supply to the Tucson CMOP facility; a $178,407.72 firm fixed-price award from VISN 15 (November 2, 2023) for Dorzolamide/Timolol ophthalmic solution to seven national CMOP locations; a $213,070.72 purchase order from VISN 15 (April 18, 2022) for multi-line pharmaceutical products including thyroid medications, acamprosate, dextrose solutions, and ophthalmic products; and a $66,784.80 purchase order from VISN 7 (March 10, 2026) for Armodafinil 30-count controlled substance tablets. All prime awards are purchase orders with firm fixed pricing and rapid completion windows (typically ten to thirty days from order receipt).

Customer concentration is extreme and singular. Across 122 prime awards totaling $5.9 million in combined potential value, the Department of Veterans Affairs accounts for 100% of the footprint, with Veterans Integrated Service Network 15 anchoring 60 awards ($3.3 million, 56% of combined potential value). VISNs 22, 7, 12, 1, and 9 together account for 52 awards ($2.7 million). The top five VISNs by award count and dollar value cover 92% to 95% of the active portfolio. Hygen has no federal customers outside the VA system and no subcontract footprint.

Activity shows volatility. The vendor received five awards in 2022, twelve in 2023, five in 2024, twelve in 2025, and one in 2026 (as of mid-July 2026). All 122 awards are obligated in full against combined potential value. One award in the source carries an 8(a) certification expiration date (March 9, 2025), indicating that Hygen's 8(a) program participation has lapsed as of the 2026-03-10 observation date, which narrows future set-aside eligibility to small disadvantaged business (SDB) self-certification and full-and-open competition. The company competes predominantly under total small business set-asides when available, with occasional full-and-open awards (two awards in the source carry "No Set-Aside Used" designation).

Hygen operates no federal IDIQs, GWACs, or BPAs. All awards are individual purchase orders issued directly by VISN network contracting offices. The vendor maintains no named teaming relationships, parent prime relationships, or subcontract engagement in the source data. The entire portfolio consists of direct-award, firm fixed-price pharmaceutical supply contracts to VA CMOPs, with order-to-delivery cycles measured in days to weeks and repeat ordering patterns across the same VISNs.

HyGen Pharmaceuticals, Inc. is a nationwide wholesale distributor of Prescription Pharmaceuticals both generic and brand-name drugs, OTC Drugs and Diabetic Medical Supplies.

23 years of experience in the commercial business sector of pharmaceutical products to independently owned retail-pharmacies, Long-term Care facilities, and small Chain-Pharmacies.

Highest quality, competitive pricing and superior service.